In-Silico discovery of 17alpha-hydroxywithanolide-D as potential neuroprotective allosteric modulator of NMDA receptor targeting Alzheimer's disease – PubMed Black Hawk Supplements

BLACK HAWK: High quality ashwagandha supplement for sleep

Published article

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline, memory impairment, and behavioral alterations. The N-methyl-D-aspartate (NMDA) receptor has emerged as a promising target for AD pharmacotherapy due to its role in the disease’s pathogenesis. This study leverages advanced computational methods to screen 80 active constituents of Withania somnifera (Ashwagandha), a traditional herb known for its neuroprotective effects, against the NMDA receptor,…
Black Hawk Supplements, best supplements in the UK

In-Silico discovery of 17alpha-hydroxywithanolide-D as potential neuroprotective allosteric modulator of NMDA receptor targeting Alzheimer's disease - PubMed

In-Silico discovery of 17alpha-hydroxywithanolide-D as potential neuroprotective allosteric modulator of NMDA receptor targeting Alzheimer’s disease

Manoj Kumar Vashisth et al. Sci Rep. .

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline, memory impairment, and behavioral alterations. The N-methyl-D-aspartate (NMDA) receptor has emerged as a promising target for AD pharmacotherapy due to its role in the disease’s pathogenesis. This study leverages advanced computational methods to screen 80 active constituents of Withania somnifera (Ashwagandha), a traditional herb known for its neuroprotective effects, against the NMDA receptor, using FDA-approved Ifenprodil as a reference. Our blind virtual screening results demonstrated that all tested compounds could bind to various domains of the NMDA receptor, with binding energies ranging from – 4.1 to -11.9 kcal/mol, compared to Ifenprodil’s -7.8 kcal/mol. Binding preference analysis revealed 7 compounds bound to the A-chain, 37 to the B-chain, 7 to the C-chain, and 29 to the D-chain of the receptor. Notable binding was observed predominantly at the Amino Terminal Domain (ATD) core site, some at the ATD-Ligand Binding Domain (LBD) interface, and a few at the Transmembrane Domain (TMD). Particularly, 17alpha-hydroxywithanolide D, with a binding energy of -11.9 kcal/mol, emerged as a prime candidate for further investigation. Molecular dynamics simulations of this compound revealed key interactions, including direct hydrogen bonding with residues ASP165, ARG431, THR433, LYS466, and TYR476 on the D-chain, as well as additional hydrophobic and water-bridging interactions. These simulations highlighted the compound’s influence on dynamic conformational states of the GluN1b-GluN2B receptor complex, modulating interactions between GluN1b Lys178 and GluN2B Asn184. Furthermore, the compound affected the distance between LBD heterodimers and the tension within the LBD-M30 linker, demonstrating its potential to modulate NMDA receptor activity. This comprehensive study not only underscores the therapeutic promise of Withania somnifera derivatives for AD but also provides a detailed molecular basis for their efficacy, offering valuable insights for targeted drug development and innovative therapeutic strategies against Alzheimer’s disease.

Keywords: Withania somnifera; 17alpha-hydroxywithanolide D; Alzheimer’s disease; Docking; Ifenprodil; Molecular dynamics; N-methyl-D-aspartate receptor; Virtual screening.

PubMed Disclaimer

Conflict of interest statement

Declarations Competing interests The authors declare no competing interests.

References

    1. Trompetero, A. et al. Alzheimer’s disease and Parkinson’s disease: a review of current treatment adopting a nanotechnology approach. Curr. Pharm. Design. 24 (1), 22–45 (2018). – DOI
    1. Alzheimer’s, A. 2017 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 13 (4), 325–373 (2017). – DOI
    1. Nichols, E. et al. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol. 18 (1), 88–106 (2019). – DOI
    1. Wimo, A. et al. The worldwide costs of dementia in 2019. Alzheimer’s & Dementia (2023).
    1. Prince, M. et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s Dement. 9 (1), 63–75 (2013). – DOI

MeSH terms

Substances

Grants and funding

BLACK HAWK: Best lions mane supplement for women

Read the original publication:

In-Silico discovery of 17alpha-hydroxywithanolide-D as potential neuroprotective allosteric modulator of NMDA receptor targeting Alzheimer's disease – PubMed